Morning Briefing: Kommt die erste Krebsimpfung schon im kommenden Jahr?
Moderna und der US-Partner Merck legen Studien für einen neuen Krebsimpfstoff vor – und nähren damit nicht nur die Fantasie der Anleger. Mit mRNA könnten Tumore per Impfung verhindert werden.
Good morning readers, pharmaceutical giants Moderna and Merck & Co. announced yesterday that millions of people worldwide could soon benefit from the results of a study on a new cancer vaccine. According to the companies, the tested personalized cancer vaccine reduced the risk of certain malignant skin tumors recurring or spreading to distant areas of the body.
If the results prove accurate, this could be a breakthrough in the fight against cancer. The vaccine relies on mRNA technology, which Moderna promises to use for various cancer variants. CEO Stéphane Bancel is convinced that the technology will form the basis for a lucrative new era. The global market for mRNA therapeutics is expected to grow by nearly 20 percent to around $21.5 billion by 2030, according to an analysis by the London Stock Exchange Group.
Moderna is competing with the German company Biontech for the development of these substances. Since yesterday, investors have once again placed their faith in Moderna, with the stock soaring by 176 percent on Wednesday. What went unnoticed in the rather cool investor mood is that the substance could not only help many people, but also rapidly.
If the further approval process proceeds without unpleasant surprises, the substance will be available next year.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
